Azithromycin is the Most Appropriate Management
For this 5-month-old infant with classic pertussis presentation (paroxysmal cough, post-tussive vomiting, cyanotic episodes, and marked lymphocytosis), azithromycin is the definitive treatment. The answer is A. Azithromycin.
Clinical Reasoning
This infant presents with the pathognomonic triad of pertussis:
- Paroxysmal cough with post-tussive vomiting (classic whooping cough)
- Cyanotic episodes (indicating severe disease)
- Marked lymphocytosis (WBC 27,000/L with 80% lymphocytes = ~21,600 lymphocytes/L)
The 10-day history places this in the catarrhal-to-paroxysmal phase where antimicrobial therapy is most critical to reduce transmission and potentially modify disease severity, particularly in this vulnerable age group where mortality risk is highest 1.
Why Azithromycin is the Correct Choice
According to CDC guidelines, azithromycin is the preferred macrolide for infants aged <6 months 1. The specific dosing for this 5-month-old is:
- 10 mg/kg per day for 5 days (single daily dose) 1
Advantages Over Other Macrolides in This Age Group:
- Safer than erythromycin: Erythromycin carries significant risk of infantile hypertrophic pyloric stenosis (IHPS) in infants <1 month and is less well-tolerated in young infants 1
- Better tolerability: Fewer gastrointestinal side effects compared to erythromycin 1
- Convenient dosing: Once-daily administration improves adherence versus erythromycin's 4-times-daily regimen 1
- Shorter course: 5 days versus 14 days for erythromycin 1
Why Other Options Are Incorrect
B. Ceftriaxone
- No activity against Bordetella pertussis
- Cephalosporins are not effective for pertussis treatment
- This would be appropriate for bacterial pneumonia or meningitis, but not pertussis
C. Nebulized Salbutamol
- Does not treat the underlying infection
- Bronchodilators have no role in pertussis management
- The cough is due to toxin-mediated airway damage, not bronchospasm
- May provide minimal symptomatic relief but does not address the disease
D. Corticosteroids
- No proven benefit in pertussis
- Not recommended in guidelines [1-1
- The pathophysiology involves bacterial toxins, not primarily inflammation amenable to steroid therapy
Critical Management Considerations
Severity Assessment
This infant has severe pertussis based on:
- Age <6 months (highest risk group for mortality) 1
- Cyanotic episodes (indicating hypoxemia)
- Marked lymphocytosis (>20,000 lymphocytes/L is associated with severe disease and pulmonary hypertension risk) 2, 3, 4
Additional Management Beyond Antibiotics
While azithromycin is the answer to this question, recognize that this infant requires:
- Hospitalization with intensive monitoring for apnea, hypoxemia, and feeding difficulties
- Close monitoring for malignant pertussis (extreme leukocytosis >50,000/L with lymphocytosis can cause pulmonary hypertension and death) 2, 3, 4
- Supportive care: Oxygen, gentle suctioning, minimal stimulation to prevent paroxysms
- Contact tracing and prophylaxis for household members 1
Common Pitfalls to Avoid
Delaying antibiotic therapy: Even though antibiotics primarily reduce transmission rather than dramatically alter clinical course once paroxysmal phase begins, they should be started immediately in infants due to high mortality risk 1
Using erythromycin instead of azithromycin: While erythromycin is cheaper and was historically first-line, azithromycin is specifically preferred for infants <6 months due to better safety profile 1
Treating as bronchiolitis or asthma: The marked lymphocytosis and post-tussive vomiting distinguish pertussis from viral bronchiolitis
Underestimating severity: Infants <6 months with pertussis and lymphocytosis >20,000/L require intensive monitoring as they can rapidly deteriorate with pulmonary hypertension 2, 3, 4
Missing the diagnosis entirely: In the acute care setting, lymphocytosis in an infant with cough should immediately raise suspicion for pertussis 5, 6